Last reviewed · How we verify
Experimental for steroid
This experimental steroid modulates inflammatory and immune responses through glucocorticoid receptor signaling.
This experimental steroid modulates inflammatory and immune responses through glucocorticoid receptor signaling. Used for Inflammatory or autoimmune condition (specific indication not publicly disclosed).
At a glance
| Generic name | Experimental for steroid |
|---|---|
| Sponsor | Assistance Publique - Hôpitaux de Paris |
| Drug class | Corticosteroid |
| Target | Glucocorticoid receptor |
| Modality | Small molecule |
| Therapeutic area | Immunology / Inflammation |
| Phase | Phase 3 |
Mechanism of action
Steroids work by binding to glucocorticoid receptors in the cytoplasm, translocating to the nucleus, and modulating gene expression to suppress inflammatory cytokine production and immune cell activation. As an experimental formulation from AP-HP, this agent likely represents a novel delivery system, dosing regimen, or chemical modification of existing corticosteroid scaffolds aimed at improving efficacy or safety in phase 3 testing.
Approved indications
- Inflammatory or autoimmune condition (specific indication not publicly disclosed)
Common side effects
- Hyperglycemia
- Hypertension
- Immunosuppression / increased infection risk
- Osteoporosis
- Mood disturbances
Key clinical trials
- Testing the Investigational Medication Combination of Teclistamab and Pomalidomide Compared to the Usual Treatment (Carfilzomib, Pomalidomide, and Dexamethasone) for Patients With Multiple Myeloma Who Have Relapsed Shortly After Treatment (PHASE1, PHASE2)
- Testing the Investigational Medication Combination of Daratumumab and Teclistamab Compared to the Usual Treatment (Daratumumab, Pomalidomide, Dexamethasone or Daratumumab, Carfilzomib, Dexamethasone) for Patients With High-risk Multiple Myeloma Refractory or in First Relapse (PHASE2)
- Multi-arm Multi-modality Therapy for Very High Risk Localized and Low Volume Metastatic Prostatic Adenocarcinoma (PHASE2)
- A Study to Learn How Safe and How Well Linvoseltamab Works Compared to Standard Treatment in Adult Patients With Multiple Myeloma Who Are Not Eligible for Transplant (PHASE3)
- Study of Selinexor With Carfilzomib, Isatuximab and Dexamethasone for Patients With Relapsed and/or Refractory Multiple Myeloma (PHASE1, PHASE2)
- Ribociclib And Endocrine Treatment of Physician's Choice for Locoregional Recurrent, Resected Hormone Receptor Positive HER2 Negative Breast Cancer (PHASE2)
- SHAPE-ENDO: Multimodal Pre-Surgical Optimization in Patients With Obesity and Early-Stage Endometrial Cancer
- A Study to Evaluate Investigational Agents With or Without Pembrolizumab (MK-3475) in Participants With Advanced Esophageal Cancer Previously Exposed to Programmed Cell Death 1 Protein (PD-1)/ Programmed Cell Death Ligand 1 (PD-L1) Treatment (MK-3475-06B) (PHASE1, PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Experimental for steroid CI brief — competitive landscape report
- Experimental for steroid updates RSS · CI watch RSS
- Assistance Publique - Hôpitaux de Paris portfolio CI